Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer

　　 Precision Strikes on MET:A New Era in Lung Cancer Therapy 

　　A landmark advancement has emerged in targeted lung cancer treatment.MET alterations(including METex14 skipping mutations and amplifications)drive a subset of NSCLC cases,where conventional therapies often fail.Novartis’Capmatinib(Tabrecta®/妥瑞达®),an oral,highly selective MET tyrosine kinase inhibitor(TKI),has revolutionized outcomes by precisely blocking aberrant MET signaling,halting tumor proliferation and metastasis.

　　 Drug Profile:The‘Precision Missile’Against MET Dysregulation 

　　Capmatinib targets the MET receptor’s ATP-binding site,effectively neutralizing oncogenic activity triggered by METex14 skipping mutations.This targeted blockade disrupts cancer cell growth and invasion,positioning it as a‘game-changer’for affected patients.

　　 Clinical Validation:Reshaping Survival Outcomes 

　　The multicenter GEOMETRY study established Capmatinib’s efficacy:

　　- Treatment-Naïve Patients: ORR 67.9%,DCR 89.5%,median PFS 12.4 months,OS 21.4 months.

　　- Previously Treated Patients: ORR 40.6%,DCR 78.3%,median DOR 9.72 months.

　　- Brain Metastases: Intracranial ORR 54%(CR 23%),DCR 92%,addressing a critical unmet need.

　　Chinese cohort data echoed these robust outcomes with manageable safety profiles.

　　 Administration&Safety Management 

　　- Dosage: 400mg twice daily orally,with or without food.

　　- AE Management: Common peripheral edema(50–60%,mostly mild–moderate)can be managed with supportive measures.Nausea,fatigue,and ALT elevations are typical;dose adjustments/interruptions may be required for Grade≥3 events.Monitor closely for hepatotoxicity and pneumonitis.

　　 Global Accessibility:Diverse Options for Patients 

　　- Originator Drug: HK$20K+per box(approx.),EU$50K+.

　　- Generic Alternatives: Lao generics priced at US$200–300,offering cost-effective access while maintaining bioequivalence.

　　- Purchasing Guidance: Obtain through reputable channels,adhere to physician supervision,and conduct regular monitoring.

　　 Future Horizons:Combo Therapies&Resistance Overcomes 

　　- Combination Strategies: Ongoing trials explore synergies with immunotherapy,chemotherapy,or anti-angiogenics to enhance durability.

　　- Resistance Mechanisms: Studies identify MET D1228 mutations,bypass pathways(EGFR/BRAF),and histological transformation,guiding next-gen MET TKI development.

　　- Therapeutic Expansion: Investigations extend to neoadjuvant/adjunctive settings in early-stage disease,and beyond NSCLC(e.g.,gastric,hepatic cancers).